Tesamorelin can cause water retention as it stimulates the growth hormone (GH) and insulin-like growth factor-1 (IGF-1) pathway, which affects how the body regulates sodium, fluids, and tissue hydration [1–6]. Tesamorelin causes water retention primarily by increasing hormonal activity related to the body's sodium and water balance. Increased GH and IGF-1 activity can lead to mild fluid accumulation in some individuals, presenting as swelling, puffiness, bloating, or mild tissue oedema, which is a build-up of fluid in the body's tissues.
Clinical trials have repeatedly reported mild oedema and fluid retention in some individuals using tesamorelin. In Phase III trials conducted by Falutz et al. (2007, 2010), peripheral oedema, swelling, and injection site reactions were among the more frequently reported adverse events during treatment [2,3]. Long-term safety studies have also noted mild symptoms of fluid retention in some participants, though these effects were generally deemed manageable and not severe [4].
Water retention associated with tesamorelin is typically mild and transient, not dangerous. Some individuals may notice:
- Mild swelling of the hands, feet, or ankles
- Facial swelling
- Temporary weight fluctuations
- A feeling of tightness in rings, shoes, or clothes
- Mild bloating
The severity of fluid retention can vary depending on factors such as dose, individual sensitivity to GH signalling, baseline metabolic status, renal function, and the degree of IGF-1 level increase during therapy [1–6]. Individuals experiencing a greater increase in IGF-1 may be more susceptible to oedema-related symptoms.
Importantly, the majority of studies on tesamorelin have shown that fluid retention has not typically led to serious cardiovascular or metabolic complications in appropriately qualified participants [2–5]. Overall, clinical trials have described tesamorelin as being relatively well tolerated, despite occasional symptoms of oedema or water retention.
To limit water retention during tesamoline therapy, the following supportive strategies are often discussed:
- Monitoring sodium and salt intake
- Maintaining adequate hydration
- Limiting excessive alcohol consumption
- Monitoring of IGF-1 levels during treatment
- Dose adjustment under medical supervision if symptoms worsen
- Regular physical activity that supports circulation
Because tesamorelin affects hormonal and metabolic pathways, persistent or worsening oedema should be assessed by a doctor to rule out an excessive GH or IGF-1 response, cardiovascular issues, renal dysfunction or other underlying conditions.
A meta-analysis conducted by Badran et al. (2026) also confirmed that tesamorelin can cause adverse events, such as joint pain, muscle pain, tingling, injection site reactions, and symptoms related to oedema, although serious adverse events generally remained relatively rare [6].
Generally speaking, water retention associated with tesamorelin appears to be primarily driven by the activation of the GH–IGF-1 axis, which temporarily alters the body's sodium and fluid handling. In most clinical trials, this effect has been mild, manageable, and often considered less significant than the benefits of visceral fat reduction and improved metabolic health observed in many participants.
Disclaimer
The content is for educational and scientific information purposes only and should not be construed as medical advice, diagnosis, or therapeutic recommendation. Tesamorelin affects hormonal pathways and can cause fluid retention and other adverse effects requiring medical monitoring. Individuals experiencing persistent swelling, water retention, or other concerning symptoms should consult a qualified healthcare professional.
References
- Tesamorelin. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. (2018). Tesamorelin. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Available at: NCBI Tesamorelin Overview
- Falutz J, Allas, S., Blot, K., et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. The New England Journal of Medicine, 357(23), 2359–2370. https://doi.org/10.1056/NEJMoa072375
- Falutz J, Mamputu, J. C., Potvin, D., et al. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analogue, in human immunodeficiency virus-infected patients with excess abdominal fat: A pooled analysis of two multicentre, double-blind placebo-controlled phase 3 trials with safety extension data. The Journal of Clinical Endocrinology & Metabolism, 95(9), 4291–4304. https://doi.org/10.1210/jc.2010-0490
- Falutz J, Allas, S., Mamputu, J. C., et al. (2008). Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS(14), 1719–1728. https://doi.org/10.1097/QAD.0b013e32830a5058
- Rahman F, McLaughlin, T., Mesquita, P., et al. (2023) Effect of tesamorelin in people with HIV with and without dorsocervical fat: post hoc analysis of phase III double-blind placebo-controlled trial. Journal of Clinical and Translational Science, 7(1), e40. https://doi.org/10.1017/cts.2022.515
- Badran AS, Helal, A., Shata, K. S., & Ayesh, H. (2026). Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomised controlled trials. Obesity Research & Clinical Practice, 20(1), 2–12. https://doi.org/10.1016/j.orcp.2026.01.002